Loading...
Market
Which country will be the next to approve CASGEVY™ by end of 2024?
2
Resolution / Starting Odds
United States • 25%
Canada • 25%
Germany • 25%
Other • 25%
Official announcements from respective national health authorities
Story
CASGEVY™ CRISPR-Based Therapy for Beta Thalassemia Approved in England
Aug 7, 2024, 11:25 PM
Patients in England suffering from a rare blood disorder known as transfusion-dependent beta thalassemia will soon have access to the world's first CRISPR-based medicine, CASGEVY™. This development follows a reimbursement agreement reached between Vertex Pharmaceuticals and U.K. officials. The National Health Service (NHS) will begin rolling out the gene therapy, which is a collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics, marking a significant advancement in the treatment of this condition.
View original story
Similar markets
United States • 25%
European Union • 25%
China • 25%
Other • 25%
United States • 25%
United Kingdom • 25%
Germany • 25%
Other • 25%
United Kingdom • 25%
Canada • 25%
Australia • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
United States • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
European Union • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%
United States • 25%
European Union • 25%
United Kingdom • 25%
Other • 25%
USA • 25%
UK • 25%
Germany • 25%
Other • 25%
European Union • 25%
Canada • 25%
Japan • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%